HALOZYME THERAPEUTICS Business Summary

Halozyme Therapeutics operates a high-margin, royalty-driven business model centered on its proprietary ENHANZE drug delivery technology, which utilizes the rHuPH20 enzyme to facilitate the subcutaneous administration of traditionally intravenous biologics. The company generates revenue through three primary streams: recurring royalties on partner sales (notably from Roche’s Phesgo and Janssen’s Darzalex FASPRO), milestone payments for regulatory and commercial achievements, and product sales from its Hylenex recombinant and the auto-injector platforms acquired via Antares Pharma. Its operations are segmented into the ENHANZE licensing business and the specialty product/device segment, which focuses on proprietary pressure-assisted drug delivery systems. In the competitive landscape, Halozyme faces pressure from delivery system manufacturers like West Pharmaceutical Services and Gerresheimer, as well as biosimilar developers like Xbrane Biopharma. However, Halozyme maintains a dominant market position as the industry standard for large-volume subcutaneous delivery, protected by an extensive patent estate and deep integration into the pipelines of nearly all top-tier global pharmaceutical firms. Halozyme was co-founded in 1998 by Gregory Frost and Robert J. Little, evolving from a specialized biotech startup into a diversified platform powerhouse. The company is currently led by President and CEO Dr. Helen Torley, a veteran executive with prior leadership roles at Amgen and Bristol-Myers Squibb, who is credited with pivoting the company toward its successful royalty-centric strategy. The executive leadership team includes CFO Nicole LaBrosse, who oversees the firm’s robust capital allocation and share buyback programs, and Dr. Michael J. LaBarre, serving as Chief Technical Officer with deep expertise in enzyme engineering and product development. The board of directors features prominent industry figures such as Dr. Jeffrey W. Henderson, former CFO of Cardinal Health, and the company maintains a strong institutional investor base led by The Vanguard Group and BlackRock, reflecting its status as a stable, cash-flow-positive entity within the mid-cap biotechnology sector.